Deprenyl (selegiline) in the treatment of Parkinson's disease
The DOI matches its Crossref record.
Abstract
Deprenyl combined with levodopa and a peripheral decarboxylase inhibitor is of therapeutic value in the treatment of Parkinson's disease. This conclusion is substantiated by the improvement of akinesia, on-off phases, fluctuations of disability and rigidity. Levodopa doses can be reduced. The onset of adverse reactions is later and side-effects are even milder when compared to those with combined levodopa treatment. The most significant effect of deprenyl, however, is its ability to prolong the life expectancy of parkinsonian patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Depression and Parkinson's disease: a review
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.443 · Cited by 1,111
Parkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage
Morgenstern, L. B., Demchuk, A. M., Kim, D. H., Frankowski, R. F., & Grotta, J. C. (2001) · Neurology · doi:10.1212/wnl.56.10.1294 · Cited by 316
Burn, D. J. (2002) · Movement Disorders · doi:10.1002/mds.10114 · Cited by 223
Prevalence and treatment of depression in Parkinson's disease
Veazey, C., Ozlem Erden Aki, S., Cook, K. F., Lai, E. C., & Kunik, M. E. (2005) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.17.3.310 · Cited by 162
Metadata
- Authors
- BIRKMAYER, W.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Wiley
- Published
- 1983-07
- Volume
- 68
- Pages
- 103-106
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W2025537689
- Cited by
- 39
- References
- 0
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deprenyl (selegiline) in the treatment of Parkinson's disease. https://app.cochat.ai/papers/10.1111/j.1600-0404.1983.tb01522.x
- The paper
- BIRKMAYER, W. (1983). Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.1983.tb01522.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.